AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 162 min read$INCY

Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2%

Incyte Genomics Inc (INCY) reported $5.1B in revenue for fiscal year 2025, a 21.2% increase from the prior year. Trailing 12-month revenue was $5.4B. The company's revenue has grown from $94.5M in 2011 to $5.1B in 2025. Q1 2026 revenue was $1.3B, up 20.9% year-over-year.

Original reporting
stocktitan.net
Published Sep 16, 2026, 3:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 5:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INCY
Bullish
high confidence
Mentioned
$INCY
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$INCYBullishMed
01

Why it matters

The fresh revenue numbers represent the first public disclosure of FY2025 performance, offering traders new data to assess valuation.

02

Market read

New earnings data for a mid‑cap biotech, relevant for sector‑specific trading decisions.

03

What to watch

Guidance for FY2026 and profitability metrics were not disclosed.

Relevance 7/10Novelty 8/10Timing: post‑earnings release

Background

The article provides a summary of Incyte Genomics' recent revenue figures without additional commentary.

Company-level read

Ticker impact

$INCYBullishHigh confidence
Context

Incyte Genomics reported FY2025 revenue of $5.1B, up 21.2% YoY, and TTM revenue of $5.4B.

Expected impact

Potential upside as investors price in accelerated growth.

Evidence & confidence

Double‑digit YoY revenue increase for a mid‑cap biotech is material and fresh.

Market effects

Sector

Biotech sector may benefit from demonstrated revenue growth trends.

Regional

U.S. biotech investors could see increased buying pressure.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Revenue growth may be offset by higher R&D spend, pressuring margins.

Key entities

  • company
    Incyte Genomics Inc

    Biotech firm reporting FY2025 revenue.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 30
$INCYHigh

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.

yahoo.com2 min
AUG 28
$INCYHighAI 9/10

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Incyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.

insidermonkey.com3 min
AUG 28
$INCYHighAI 8/10

How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story

Incyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.

simplywall.st2 min